Neuromuscular

Here's what is coming soon to NeurologyLive.

MR imaging revealed minimal fat infiltration in the SRP-9001 arm compared to participants with DMD from the natural history cohort.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 8, 2021.

The Expanded Access Program will offer treatment for patients with ALS who have completed the phase 3 clinical trial and will not interfere with data or regulatory timelines.

The 3-part educational program is sponsored by Genentech.

The executive director of the Norman Fixel Institute for Neurological Diseases explained how disease-based registries play a crucial part in changing the approval system for neurologic devices in rare diseases.

A recent analysis of UnitedHealthcare insurance claims revealed increases of almost 200% for some services between 2001 and 2016.

Objective reduction in tremor was accompanied by improvement in specific motor tasks and a larger proportion of patients in the botulinum neurotoxin group reporting a global subjective improvement in symptoms.

The assistant professor of neurology and anesthesiology at Harvard Medical School provided context on the potential of motor neuron excitability in patients with ALS.

The director of the Healey & AMG Center for ALS spoke to the recent topline results of a phase 3 study of NurOwn in patients with the neuromuscular disease.

Here's what is coming soon to NeurologyLive.

Researchers from the University of Turin also found that an NEFH variant showed a protective association with ALS.

Neurology News Network for the week ending January 2, 2021.

Catch up on the best and most listened to episodes of the NeurologyLive Mind Moments podcast, featuring exclusive interviews with experts in neurology.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Jennifer Frontera, MD, and a number of others.

Look back on some of our most popular video interviews with experts in the field, including discussions on stroke, migraine, Parkinson disease, dementia, and more.

The approvals introduced several new agents into a number of patient populations, including much-needed additions to some diseases lacking a large number of options.

Catch up on some of our most popular Peer Exchange panels with experts in the field, including discussions on epilepsy, migraine, multiple sclerosis, and more.

Here's what is coming soon to NeurologyLive.

NeurologyLive compiled a number of interviews and conversations with leaders within the neurology community to discuss the neurologic symptoms associated with COVID-19.

NeurologyLive compiled a number of interviews and conversations with leaders within the neurology community to discuss how the pandemic affected mental health, specifically at an in-hospital setting.

NeurologyLive conducted a number of interviews and conversations with leaders within the neurology community to discuss the resources and tools used to adapt to the COVID-19 pandemic.

The Merz Therapeutics product, marketed as Xeomin, is the first and only FDA-approved neuromodulator available for patients aged 2 years and older with chronic sialorrhea.

NeurologyLive conducted a number of interviews and conversations with leaders within the neurology community to discuss whether the COVID-19 pandemic forced clinicians to change treatment regimens or prescriptions.

NeurologyLive conducted a number of interviews and conversations with leaders within the neurology community to assess how the COVID-19 virus affected the pathology of neurologic disorders.